



Enamine's IDD Platform Boosts ABX-CRO's Translational Medicine Approach towards Imaging Agents and Radiopharmaceuticals

[FOR IMMEDIATE RELEASE]

January 16th, 2026

ABX-CRO Leverages Enamine's Target-Agnostic Expertise in Biology, Drug Design, and Medicinal Chemistry

Dresden, Germany / Frankfurt, Germany / Kyiv, Ukraine / Wrocław, Poland, 16 January 2026 — ABX-CRO and Enamine initiated their cooperation in 2024. Since then, Enamine supports ABX-CRO with its integrated competencies in biology, chemistry, and computational sciences through its research centers in Frankfurt/Germany, Kyiv/Ukraine, and Wrocław/Poland. The initial relationship proved to be highly productive, securing innovation in short research cycles and utilizing resources at its highest return on investment. In consequence of this success, ABX-CRO and Enamine continue to deepen their relationship for the future.

Enamine's profound knowledge of chemical space, namely with its REAL compounds, the world's largest collection of make-on-demand small molecules that represents a significant fraction of such synthetically accessible chemical space. Its member molecules are REadily Accessible through validated parallel synthesis protocols using qualified in-stock building blocks.

In combination with its expanded capabilities in medicinal chemistry and computer-aided drug design, and its optimized research logistics, Enamine accomplishes design-make-test-analyze cycles of small molecules in drug discovery within days rather than weeks. Enamine Germany in Frankfurt enables support of rapid lead optimization and project management. Enamine's capabilities in biology, from hit identification, lead optimization, and translating into preclinical proof-of-concept studies, are critically supported by its biology research centers in Kyiv and Wrocław through their high-throughput screening, *in vitro* ADME, and *in vivo* PK/Tox, and other biological capabilities.

Andreas Fintelmann, Managing Director of ABX-CRO: *"We are glad and honored to continue our work and collaboration with Enamine Germany, as well as Enamine Ukraine and Poland, as important key partners of ABX-CRO. The flexibility and productive output are impressive, and the Enamine team is very competent, highly responsive, and professional. Project deadlines were always met, and we experienced excellent project management and reporting overall. This outstanding scientific focus of Enamine is possible because of its unique integrated drug discovery (IDD) platform. The Enamine colleagues are able to facilitate quick route scouting and upscaling to high quality under time pressure and in quantities enabling *in vivo* studies. Enamine's impressive biological capacities are used and highly appreciated by us for *in vivo* studies, too."*

Sven Wagner, PhD, Vice President of Partnerships at Enamine: *"We are pleased to expand our partnership with ABX-CRO and the radiopharma-cluster in Saxony, Germany by supporting their cutting-edge approach in preclinical proof-of-concept research for nuclear medicine and theranostics. Together, we have a proven, exceptional, innovative, and agile team of experts supporting the highly patient-centric focus of ABX-CRO, advancing medical progress in nuclear medicine without delay."*

Company Summaries:

About ABX-CRO

ABX-CRO is specialised in the field of pre-clinical and clinical contract research involving functional imaging methodologies with emphasis on molecular imaging with PET and SPECT. Study design, placement, regulatory set-up, project management, clinical monitoring as well as

technical quality assurance of imaging devices, collection, handling, analysis and reporting of image data is within the scope of its current activities, as well as the development of own pharmaceutical drug candidates.

For more information, please visit: www.abx-cro.com

About Enamine

Enamine is the leading provider of chemical compounds and a scientifically driven, integrated discovery Contract Research Organisation for integrated discovery with unique partnering opportunities in exploring new chemical space. The company combines access to the in-house produced screening compounds (4.5 million in stock) and building blocks (350,000 in stock) with a comprehensive platform of integrated discovery services in bioinformatics, biology, and chemistry to advance and accelerate the efforts in drug discovery.

For more information, please visit: enamine.net/

Contact Information

For ABX-CRO advanced pharmaceutical services Forschungsgesellschaft mbH:

Andreas Fintelmann
Managing Director
Phone: +49 151 4256 3498
Email: andreas.fintelmann@abx-cro.com

For Enamine:

Yurii Moroz, DSc.
Vice President of Sales and Marketing
Email: y.moroz@enamine.net